Adimab LLC. Announces New Discovery Collaboration ith Kyowa Hakko Kirin

Published: Jan 07, 2013

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced a two-target funded discovery collaboration with Kyowa Hakko Kirin (KHK) of Tokyo, Japan. Based on the strength and flexibility of Adimab’s platform, KHK has designated a membrane protein target as the initial collaboration target. In addition, Adimab announced the receipt of milestone payments from its existing collaborations with Gilead, Biogen Idec and Novo Nordisk.

Back to news